Drugs / Recombinant Human Coagulation Factor VIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02280265 | Nov 2014 → Dec 2016 | hemophilia A | Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Coagulation Factor VIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280265 ↗ |
| Known as | ADVATE | “Recombinant Human Coagulation Factor VIII for injection(ADVATE)” NCT02280265 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Coagulation Factor VIII for injection” NCT02280265 ↗ |